MRI-Brachytheraphy of Cervical Carcinoma—A Pictorial Review for the Radiologist

M. Jiménez de la Peña, E. del Cerro Peñalver, E. Alvárez Moreno, R. Cano Alonso, V. Martínez de Vega

Department of Diagnostic Imaging, Hospital Universitario Quirón Madrid, Madrid, Spain.

DOI: 10.4236/ojrad.2012.23015                

Abstract

Exact staging of cervical malignant neoplasms is essential in the selection of the most favorable therapy. MR imaging plays a comprehensive role in primary tumor staging. It monitors response to treatment, detects recurrence and helps in the planning of radiotherapy. Patients with advanced disease usually receive external-beam radiation therapy followed by intracavitary brachytherapy with concurrent chemotherapy. Brachytherapy based on cross-sectional imaging, especially MR imaging, improves local control and overall survival. MRI-based brachytherapy allows accurate positioning of the probe and the depiction of the tumor volume contour, which also permits individualized treatment planning. In order to obtain successful radiation treatment, the radiologist must provide the radiation oncologist with adequate knowledge regarding this technique and its possible complications.

Keywords

MRI-Brachytherapy; Cervical Carcinoma; High Resolution MRI

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	C. Balleyguier, E. Sala, T. Da Cunha, et al., “Staging of Uterine Cervical Cáncer with MRI: Guidelines of the European Society of Urogenital Radiology,” European Radiology, Vol. 21, No. 5, 2011, pp. 1102-1110. Hdoi:10.1007/s00330-010-1998-x
[2]	C. Haie-Meder, B. Fevers, E. Fondrinier, M. Haugh, C. Lhomme and J. P. Guastalla, “SOR Guidelines for Concomitant Chemoradiotherapy for Patients with Uterine Cervical Cancers: Evidence Update Bulletin 2004,” Annals of Oncology, Vol. 16, No. 7, 2005, pp. 1110-1108. Hdoi:10.1093/annonc/mdi220
[3]	A. Sedlis, B. N. Bundy, M. Z. Rotman, S. S. Lentz, L. I. Muderspach and R. J. Zaino, “A Randomized Trial of Pelvic Radiation Therapy versus no Further Therapy in Selected Patients with Stage IB Carcinoma of the Cervix after Radical Hysterectomy and Pelvic Lymphadenectomy: A Gynecologic Oncology Group Study,” Gynecology Oncology, Vol. 73, No. 2, 1999, pp. 177-183. Hdoi:10.1006/gyno.1999.5387
[4]	P. G. Rose, “Concurrent Chemoradiation for Locally Advanced Carcinoma of the Cervix: Where Are We in 2006?” Annals of Oncology, Vol. 17, Suppl. 10, 2006, pp. x224-x229. Hdoi:10.1093/annonc/mdl264
[5]	S. Nag, H. Cardenes, S. Chang, et al., “Proposed Guidelines for Image-Based Intracavitary Brachytherapy for Cervical Carcinoma: Report from Image-Guided Brachytherapy Working Group,” International Journal of Radiation Oncology Biology Physics, Vol. 60, No. 4, 2004, pp. 1160-1172. Hdoi:10.1016/j.ijrobp.2004.04.032
[6]	H. Janaki, C. Zsolt, B. Péter, et al., “Application of MRI for Improved Local Control in Complex Radiotherapy of Cervical Cancer,” Archives of Oncology, Vol. 14, No. 3-4, 2006, pp. 95-100. Hdoi:10.2298/AOO0604095H
[7]	C. Le Pechoux, Y. Akine, M. Sumi, et al., “High Dose Rate Brachytherapy for Carcinoma of the Uterine Cérvix: Comparison of Two Different Fractionation Regimens,” International Journal of Radiation Oncology Biology Physics, Vol. 31, No. 4, 1995, pp. 735-741. Hdoi:10.1016/0360-3016(94)00573-7
[8]	J. C. Lindergaard, J. Overgaard, S. M. Bentzen, et al., “Is There a Radiologic Basis for Improving the Treatment of Advanced Cervical Cancer?” Monographics National Cancer Institute, Vol. 21, 1996, pp. 105-112.
[9]	P. J. Eifel, “High Dose-Rate Brachytherapy for Carcinoma of the Cervix: High Tech or High Risk?” International Journal Radiation Oncology Biology Physics, Vol. 24, No. 2, 1992, pp. 383-386. Hdoi:10.1016/0360-3016(92)90696-F
[10]	F. D. Patel, S. C. Sharma, P. S. Negi, et al., “Low Dose Rate versus High Dose Rate Brachytherapy in the Treatment of Carcinoma of the Uterine Cervix: A Clinical Trial,” International Journal Radiation Oncology Biology Physics, Vol. 28, No. 2, 1994, pp. 335-341. Hdoi:10.1016/0360-3016(94)90055-8
[11]	C. Orton, “HDR: Forget Not ‘Time’ and ‘Distance’,” International Journal of Radiation Oncology Biology Physics, Vol. 20, No. 5, 1991, pp. 1131-1132. Hdoi:10.1016/0360-3016(91)90215-P
[12]	R. Potter, T. H. Knocke, C. Fellner, et al., “Definitive Radiotherapy Based on HDR Brachytherapy with Iridium 192 in Uterine Cervix Carcinoma: Report on the Vienna University Hospital Findings (1993-1997) Compared to the Preceding Period in the Context of ICRU 38 Recommendations,” Cancer Radiotherapie, Vol. 4, 2000, pp. 159-172.
[13]	V. Viswanathan, J. Dimopoulus, C. Kirisits, et al., “Computed Tomography versus Magnetic Resonance Imaging-Based Contouring in Cervical Cancer Brachytherapy: Results of a Prospective Trial and Preliminary Guidelines for Standardized Contours,” International Journal Radiation Oncology Biology Physics, Vol. 68, No. 2, 2007, pp. 491-498. Hdoi:10.1016/j.ijrobp.2006.12.021
[14]	E. A. Barnes, G. Thomas, I. Ackerman, et al., “Prospective Comparison of Clinical and Computed Tomography Assessment in Detecting Uterine Perforation with Intracavitary Brachytherapy for Carcinoma of the Cervix,” International of Journal Gynecological Cancer, Vol. 17, No. 4, 2007, pp. 821-826. Hdoi:10.1111/j.1525-1438.2007.00888.x
[15]	A. N. Viswanathan, B. M. Buttin and A. M. Kennedy, “Oncodiagnosis Panel 2006: Ovarian, Cervical and Endometrial Cancer,” Radiographics, Vol. 28, No. 1, 2008, pp. 289-307.
[16]	C. Kirisits, S. Lang, J. Dimopoulos, D. Berger, D. Georg and R. P?tter, “The Vienna Applicator for Combined Intracavitary and Interstitial Brachytherapy of Cervical Cancer: Design, Application, Treatment Planning, and Dosimetric Results,” International Journal Radiation Oncology Biology Physics, Vol. 65, No. 2, 2006, pp. 624630. Hdoi:10.1016/j.ijrobp.2006.01.036
[17]	C. Haie-Meder, R. P?tter, E. Van Limburger, et al., “Gynaecological (GYN) GEC-ESTRO Working Group. Recommendations from Gynaecological (GYN) GEC-ESTRO Working Group (I): Concepts and Terms in 3D Image Based 3D Treatment Planning in Cervix Cancer Brachytherapy with Emphasis on MRI Assessment of GTV and CTV,” Radiotherapy and Oncology, Vol. 74, No. 3, 2005, pp. 235-245. Hdoi:10.1016/j.radonc.2004.12.015
[18]	R. P?tter, C. Haie-Meder, E. Van Limbergen, et al., “Recommendations from Gynaecological (GYN) GEC ESTRO Working Group (II): Concepts and Terms in 3D Image-Based Treatment Planning in Cervix Cancer Brachytherapy-3D Dose Volume Parameters and Aspects of 3D Image-Based Anatomy, Radiation Physics, Radiobiology,” Radiotheraphy & Oncology, Vol. 78, No. 1, 2006, pp. 67-77. Hdoi:10.1016/j.radonc.2005.11.014
[19]	The Royal College of Radiologists, “Implementing Image Guided Brachytherapy for Cervix Cancer in the United Kingdom,” 2008. https://rcr.ac.uk/docs/oncology/pdf/BFCO(09)1_cervix.pdf
[20]	A. K. Berthelsena, J. Dobbsb, E. Kjell, et al., “What’s New in Target Volume Definition for Radiologists in ICRU Report 71? How Can the ICRU Volume Definitions Be Integrated in Clinical Practice?” Cancer Imaging, Vol. 7, No. 1, 2007, pp. 104-116. Hdoi:10.1102/1470-7330.2007.0013
[21]	J. C. Dimopoulos, G. Shard, D. Berger, et al., “Systematic Evaluation of MRI Findings in Different Stages of Treatment of Cervical Cancer: Potential of MRI on Delineation of Target, Pathoanatomic Structures, and Organs at Risk,” International Journal Radiation Oncology Biology Physics, Vol. 64, No. 5, 2006, pp. 1380-1388. Hdoi:10.1016/j.ijrobp.2005.10.017
[22]	W. Irvin, L. Rice, P. Taylor, W. Anderson and B. Schneider, “Uterine Perforation at the Time of Brachytherapy for Carcinoma of the Cervix,” Gynecology Oncology, Vol. 90, No. 1, 2003, pp. 113-122. Hdoi:10.1016/S0090-8258(03)00230-0
[23]	C. J. McGinn, J. A. Stitt, D. A. Buchler and T. J. Kinsella, “Intraoperative Ultrasound Guidance during High Dose Rate Intracavitary Brachytherapy of the Uterine Cervix and Corpus,” Endocurie Hyperthermial Oncology, Vol. 8, 1992, pp. 101-104.
[24]	I. Ogino, T. Kitamura, N. Okamoto, et al., “Late Rectal Complications Following High Dose Rate Intracavitary Brachytherapy in Cancer of the Cervix,” International Journal Radiation Oncology Biology Physics, Vol. 31, No. 4, 1995, pp. 725-734. Hdoi:10.1016/0360-3016(94)00547-8
[25]	P. Narayanan, M. Nobbenhuis, K. M. Reynolds, et al., “Fistulas in Malignant Gynecologic Disease: Etiology, Imaging and Management,” Radiographics, Vol. 29, 2009, pp. 1073-1083. Hdoi:10.1148/rg.294085223
[26]	J. S. Berek, C. Howe, L. D. Lagasse and N. F. Hacker, “Pelvic Exenteration for Recurrent Gynecologic Malignancy: Survival and Morbidity Analysis of the 45 Year Experience at UCLA,” Gynecology Oncology, Vol. 99, No. 1, 2005, pp. 153-159. Hdoi:10.1016/j.ygyno.2005.05.034
[27]	P. Beddy, R. Deepa Rangarajan and E. Salas, “Role of MRI in Intracavitary Brachytherapy for Cervical Carcinoma: What the Radiologist Needs to Know?” American Journal of Radiology, Vol. 196, 2011, pp. 341-347.